AstraZeneca Announced Tagrisso Reduced The Risk Of Disease Progression Or Death By 84% In Patients With Unresectable, Stage III EGFR-mutated Lung Cancer Vs. Placebo In Laura Phase III Trial
Portfolio Pulse from Charles Gross
AstraZeneca announced that its drug Tagrisso significantly reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer compared to placebo in the LAURA Phase III trial. The results will be presented at the 2024 ASCO Annual Meeting and published in The New England Journal of Medicine.
June 02, 2024 | 6:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Tagrisso showed an 84% reduction in disease progression or death in Stage III EGFR-mutated lung cancer patients in the LAURA Phase III trial. This significant clinical result is likely to positively impact AstraZeneca's stock price.
The significant clinical results from the LAURA Phase III trial for Tagrisso, showing an 84% reduction in disease progression or death, are likely to boost investor confidence and positively impact AstraZeneca's stock price. The presentation at the ASCO Annual Meeting and publication in a prestigious journal further validate the findings.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100